Sylvain Cardin
Vanderbilt University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sylvain Cardin.
American Journal of Physiology-regulatory Integrative and Comparative Physiology | 1999
Lixin Wang; Sylvain Cardin; Vicente Martinez; Yvette Taché; K. C. Kent Lloyd
The role of CCK in mediating neuronal activity in the brain in response to dietary carbohydrate was measured by detecting Fos immunoreactivity in response to duodenal glucose load in rats after administration of the CCK-A receptor antagonist devazepide. In adult, male Sprague-Dawley rats, infusion for 30 min of 545 mg (2.18 kcal) dextrose through a duodenal cannula induced Fos expression in the nucleus of the solitary tract (NTS), area postrema (AP), lateral division of the central nucleus of the amygdala (CeAL), and the external subnucleus of the lateral parabrachial nucleus (LPBE). Devazepide treatment (1 mg/kg) attenuated Fos expression in the NTS and AP by 81 and 78%, respectively, but not in the CeAL or LPBE. These results indicate that central neuronal activation is elicited by dietary glucose in the intestinal lumen and that activation of neurons in the NTS and AP is mediated by CCK-A receptors.The role of CCK in mediating neuronal activity in the brain in response to dietary carbohydrate was measured by detecting Fos immunoreactivity in response to duodenal glucose load in rats after administration of the CCK-A receptor antagonist devazepide. In adult, male Sprague-Dawley rats, infusion for 30 min of 545 mg (2.18 kcal) dextrose through a duodenal cannula induced Fos expression in the nucleus of the solitary tract (NTS), area postrema (AP), lateral division of the central nucleus of the amygdala (CeAL), and the external subnucleus of the lateral parabrachial nucleus (LPBE). Devazepide treatment (1 mg/kg) attenuated Fos expression in the NTS and AP by 81 and 78%, respectively, but not in the CeAL or LPBE. These results indicate that central neuronal activation is elicited by dietary glucose in the intestinal lumen and that activation of neurons in the NTS and AP is mediated by CCK-A receptors.
American Journal of Physiology-endocrinology and Metabolism | 1997
Patricia A. Jackson; Michael J. Pagliassotti; Masakazu Shiota; Doss W. Neal; Sylvain Cardin; Alan D. Cherrington
Our aim was to determine whether vagal transmission is required for the hormonal response to insulin-induced hypoglycemia in 18-h-fasted conscious dogs. Hollow coils were placed around the vagus nerves, with animals under general anesthesia, 2 wk before an experiment. On the day of the study they were perfused with -15 degrees C ethanol for the purpose of blocking vagal transmission, either coincident with the onset of insulin-induced hypoglycemia or after 2 h of established hypoglycemia. In a separate study the coils were perfused with 37 degrees C ethanol in a sham cooling experiment. The following parameters were measured: heart rate, arterial plasma glucose, insulin, pancreatic polypeptide, glucagon, cortisol, epinephrine, norepinephrine, glycerol, free fatty acids, and endogenous glucose production. In response to insulin-induced hypoglycemia (42 mg/dl), plasma glucagon peaked at a level that was double the basal level, and plasma cortisol levels quadrupled. Plasma epinephrine and norepinephrine levels both rose considerably to 2,135 +/- 314 and 537 +/- 122 pg/ml, respectively, as did plasma glycerol (330 +/- 60%) and endogenous glucose production (150 +/- 20%). Plasma free fatty acids peaked at 150 +/- 20% and then returned to basal levels by the end of the study. The hypoglycemia-induced changes were not different when vagal cooling was initiated after the prior establishment of hypoglycemia. Similarly, when vagal cooling occurred concurrently with the initiation of insulin-induced hypoglycemia (46 mg/dl), there were no significant differences in any of the parameters measured compared with the control. Thus vagal blockade did not prevent the effect on either the hormonal or metabolic responses to low blood sugar. Functioning vagal afferent nerves are not required for a normal response to insulin-induced hypoglycemia.Our aim was to determine whether vagal transmission is required for the hormonal response to insulin-induced hypoglycemia in 18-h-fasted conscious dogs. Hollow coils were placed around the vagus nerves, with animals under general anesthesia, 2 wk before an experiment. On the day of the study they were perfused with -15°C ethanol for the purpose of blocking vagal transmission, either coincident with the onset of insulin-induced hypoglycemia or after 2 h of established hypoglycemia. In a separate study the coils were perfused with 37°C ethanol in a sham cooling experiment. The following parameters were measured: heart rate, arterial plasma glucose, insulin, pancreatic polypeptide, glucagon, cortisol, epinephrine, norepinephrine, glycerol, free fatty acids, and endogenous glucose production. In response to insulin-induced hypoglycemia (42 mg/dl), plasma glucagon peaked at a level that was double the basal level, and plasma cortisol levels quadrupled. Plasma epinephrine and norepinephrine levels both rose considerably to 2,135 ± 314 and 537 ± 122 pg/ml, respectively, as did plasma glycerol (330 ± 60%) and endogenous glucose production (150 ± 20%). Plasma free fatty acids peaked at 150 ± 20% and then returned to basal levels by the end of the study. The hypoglycemia-induced changes were not different when vagal cooling was initiated after the prior establishment of hypoglycemia. Similarly, when vagal cooling occurred concurrently with the initiation of insulin-induced hypoglycemia (46 mg/dl), there were no significant differences in any of the parameters measured compared with the control. Thus vagal blockade did not prevent the effect on either the hormonal or metabolic responses to low blood sugar. Functioning vagal afferent nerves are not required for a normal response to insulin-induced hypoglycemia.
Diabetes | 2001
Dale S. Edgerton; Sylvain Cardin; Maya Emshwiller; Doss W. Neal; Visvanathan Chandramouli; William C. Schumann; Bernard R. Landau; Luciano Rossetti; Alan D. Cherrington
American Journal of Physiology-endocrinology and Metabolism | 2000
Patricia A. Jackson; Sylvain Cardin; Christopher S. Coffey; Doss W. Neal; Eric J. Allen; Angelina R. Penaloza; Wanda L. Snead; Alan D. Cherrington
American Journal of Physiology-endocrinology and Metabolism | 2002
Sylvain Cardin; Konstantin Walmsley; Doss W. Neal; Phillip E. Williams; Alan D. Cherrington
American Journal of Physiology-endocrinology and Metabolism | 2003
Michael D. Jensen; Sylvain Cardin; Dale S. Edgerton; Alan D. Cherrington
Journal of Applied Physiology | 1999
Sylvain Cardin; Maya Emshwiller; Patricia A. Jackson; Wanda L. Snead; Jon R. Hastings; Dale S. Edgerton; Alan D. Cherrington
American Journal of Physiology-endocrinology and Metabolism | 2004
Mary Courtney Moore; Sylvain Cardin; Dale S. Edgerton; Ben Farmer; Doss W. Neal; Margaret Lautz; Alan D. Cherrington
Diabetes | 2001
Stephanie M. Sherck; Masakazu Shiota; James Saccomando; Sylvain Cardin; Eric J. Allen; Jon R. Hastings; Doss W. Neal; P. E. Williams; Alan D. Cherrington
Diabetes | 2002
Dale S. Edgerton; Sylvain Cardin; Catherine Pan; Doss W. Neal; Ben Farmer; Margaret Converse; D Alan Cherrington.